CUBE vs MDGL · P/E 25, rev $1.07B vs rev $180.1M
CubeSmart (CUBE) versus Madrigal Pharmaceuticals Inc (MDGL) — a side-by-side from cached financials, not a winner call.
CubeSmart (CUBE) is a reit - industrial company listed on US.
Madrigal Pharmaceuticals Inc (MDGL) is a biotechnology company listed on NASDAQ.
Latest reported CUBE revenue for 2024-12-31 was $1.07B. Net income was $391.9M. Revenue was up 1.5% from 2023-12-31 to 2024-12-31. CUBE currently screens at market cap $9.69B and trailing P/E 25.0.
Latest reported MDGL revenue for 2024-12-31 was $180.1M. Net income was -$465.9M. MDGL currently screens at market cap $11.56B.
CUBE currently screens at market cap $9.69B and trailing P/E 25.0. MDGL currently screens at market cap $11.56B.
Not investment advice. Open the CUBE and MDGL stock pages for the full models.
Not investment advice.